Spots Global Cancer Trial Database for A Phase I Study of LJM716 in Japanese Patients With Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Phase I Study of LJM716 in Japanese Patients With Advanced Solid Tumors
Official Title: A Phase I Study of LJM716 in Japanese Patients With Advanced Solid Tumors
Study ID: NCT01911936
Conditions
Interventions
Study Description
Brief Summary: This study will evaluate safety and tolerability to estimate the MTDand/or recommended dose.
Detailed Description: This is a phase I, open-label, dose-escalation study to establish the MTD and/or RDE of LJM716 as single agent in Japanese patients that have advanced solid tumors. The study consists of a dose escalation part and a dose expansion part.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Novartis Investigative Site, Koto, Tokyo, Japan
Novartis Investigative Site, Fukuoka, , Japan
Contact Details
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
